Published in J Immunol on October 01, 1981
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Polymorphism of human erythrocyte C3b/C4b receptor. Proc Natl Acad Sci U S A (1983) 2.30
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Low ionic strength or chemical cross-linking of monomeric C3b increases its binding affinity to the human complement C3b receptor. Immunology (1983) 1.35
C3d receptors are expressed on human monocytes after in vitro cultivation. Proc Natl Acad Sci U S A (1983) 1.30
Lymphoblastoid cell supernatants increase expression of C3b receptors on human polymorphonuclear leucocytes: direct binding studies with 125I-C3b. Immunology (1984) 1.14
Studies in the rat of antibody-coated and N-ethylmaleimide-treated erythrocyte clearance by the spleen. I. Effects of in vivo complement activation. Immunology (1986) 0.94
Studies in the rat of antibody-sensitized and N-ethylmaleimide-treated erythrocyte clearance by the liver: effects of immune complex infusion and complement activation. Immunology (1988) 0.89
Studies in the rat of antibody-coated and N-ethylmaleimide-treated erythrocyte clearance by the spleen. II. Effects of immune complex infusion. Immunology (1986) 0.84
Anaphylatoxin C3a enhances mucous glycoprotein release from human airways in vitro. J Exp Med (1985) 0.83
Inhibition of neutrophil function by fluid phase C3b of complement. Infect Immun (1983) 0.75
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Cortical language localization in left, dominant hemisphere. An electrical stimulation mapping investigation in 117 patients. J Neurosurg (1989) 4.18
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Attainment and adjustment in two geographical areas. I--The prevalence of psychiatric disorder. Br J Psychiatry (1975) 3.79
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation (1990) 3.52
Hypoglycemic symptoms and frequency of severe hypoglycemia in patients treated with human and animal insulin preparations. Diabetes Care (1991) 3.51
Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol (1985) 3.50
Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 3.47
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
c-Jun and p53 activity is modulated by SUMO-1 modification. J Biol Chem (2000) 2.71
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care (1987) 2.50
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med (1999) 2.36
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med (1981) 2.19
Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months. Diabetologia (1983) 2.18
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. Immunology (1970) 2.14
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. Immunology (1967) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A (1981) 2.02
Sleep and depression--results from psychobiological studies: an overview. Biol Psychol (2001) 2.02
Effect of age on excess mortality in obesity. JAMA (1999) 2.01
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia (1997) 1.95
Oxidative damage to DNA: formation, measurement, and biological significance. Rev Physiol Biochem Pharmacol (1997) 1.91
Glucose metabolism in perfused skeletal muscle. Effects of starvation, diabetes, fatty acids, acetoacetate, insulin and exercise on glucose uptake and disposition. Biochem J (1976) 1.90
The formation of glutamine and alanine in skeletal muscle. J Biol Chem (1974) 1.90
Evaluation of an intensified insulin treatment and teaching programme as routine management of type 1 (insulin-dependent) diabetes. The Bucharest-Düsseldorf Study. Diabetologia (1987) 1.87
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia (1990) 1.84
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol (1995) 1.82
The complement system in host defense and inflammation. Rev Infect Dis (1980) 1.80
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats. Biochem J (1974) 1.78
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A (1973) 1.74
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol (1974) 1.73
Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med (1972) 1.73
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
Glucose metabolism in perfused skeletal muscle. Interaction of insulin and exercise on glucose uptake. Biochem J (1975) 1.71
Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci U S A (1976) 1.69
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol (1997) 1.68
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia (1993) 1.67
Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care (1985) 1.67
Issues in the measurement of satisfaction with treatment. Am J Manag Care (1997) 1.67
Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest (1990) 1.66
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies. J Clin Invest (1974) 1.65
Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J Cell Biol (1998) 1.63
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (1993) 1.63
Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis (1995) 1.63
Assessment of excess mortality in obesity. Am J Epidemiol (1998) 1.62
Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci (1993) 1.61